Default company panoramic image
Logo

Thermalin Inc.

Partnered summer 2017 with Sanofi on 2 of our 7 programs developing new insulin molecules to improve outcomes in $25 --> 70B insulin market.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Newton, MA, USA
  • Currency USD
  • Founded January 2017
  • Employees 23
  • Incorporation Type C-corp
  • Website thermalin.com

Company Summary

Thermalin is developing next-generation insulins to fill gaps in a rapidly growing $25B market. Our new molecules include ultra-concentrated, ultra-rapid-acting/fast offset meal-time and pump insulin ($7B addressable), ultra-heat stable, long- and biphasic ($8B+) insulin, glucose responsive insulins, and dermal patch insulin. Thermalin has partnered two of these programs with Sanofi and will be seeking partners for the other programs.

Team

  • Default avatar
    Michael Weiss
    Founder & Chief Innovation Officer

    Expert on insulin analog design; currently Chairman, Biochemistry & Molecular Biology, Indiana University School of Medicine, >150 publications on insulin, 4 “Paper of the Week” in JBC. Former Chair of Biochemistry and Chair of NIDDK’s Board of Scientific Councilors. MD, summa cum laude & PhD in biophysics from Harvard.

  • Default avatar
    Bruce Frank
    VP Insulin Development

    Bruce was co-inventor of Humalog and retired from Eli Lilly after 34-years in which he held several senior management positions in insulin discovery, development, manufacturing, and regulatory affairs. He received his Ph.D. in Physical Biochemistry from Northwestern and did his post-doc at Berkley.

  • Photo
    Chief Executive Officer

    Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.

  • Default avatar
    John Brooks
    Chairman

    CEO, Healthcare Capital, LLC; former CEO of Joslin Diabetes Center in Boston; founder of Prism Ventures; John serves on several life science and not-for-profit boards.

  • Default avatar
    Thomas Hattier
    VP of R & D

    Thom is an accomplished researcher, who has driven development efforts in the biotech and biopharma sectors, including at Myriad Genetics, AmpliCon, and Cellular Technology. Thom earned a BA at Connecticut College; an MS in biochemistry, PhD in pathology, and completed post-doctoral work in molecular genetics, all at Case Western Reserve University.

Advisors

  • Default avatar
    Michael Barron
    Attorney
    Unconfirmed
    Default avatar
    Stephen DiPalma,
    Unconfirmed

Previous Investors

  • Default avatar
    Massachusetts Medical Angels
    Unconfirmed
    Default avatar
    Sanofi Sunrise
    Unconfirmed